140 related articles for article (PubMed ID: 27055465)
1. Immunogenicity of Human Papillomavirus Recombinant Vaccine in Children with CKD.
Nelson DR; Neu AM; Abraham A; Amaral S; Batisky D; Fadrowski JJ
Clin J Am Soc Nephrol; 2016 May; 11(5):776-784. PubMed ID: 27055465
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study.
Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR;
Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797
[TBL] [Abstract][Full Text] [Related]
3. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
4. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old.
Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768
[TBL] [Abstract][Full Text] [Related]
6. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.
Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E
JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
Siddiqui MA; Perry CM
Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
[TBL] [Abstract][Full Text] [Related]
9. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
[TBL] [Abstract][Full Text] [Related]
10. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination.
Lazcano-Ponce E; Torres-Ibarra L; Cruz-Valdez A; Salmerón J; Barrientos-Gutiérrez T; Prado-Galbarro J; Stanley M; Muñoz N; Herrero R; Hernández-Ávila M
J Infect Dis; 2019 Jan; 219(1):41-49. PubMed ID: 30085139
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
[TBL] [Abstract][Full Text] [Related]
12. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study.
Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV
Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients.
Gomez-Lobo V; Whyte T; Kaufman S; Torres C; Moudgil A
Pediatr Transplant; 2014 May; 18(3):310-5. PubMed ID: 24484551
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children.
MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M
Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women.
Kahn JA; Xu J; Kapogiannis BG; Rudy B; Gonin R; Liu N; Wilson CM; Worrell C; Squires KE
Clin Infect Dis; 2013 Sep; 57(5):735-44. PubMed ID: 23667266
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, V and VD.
Praditpornsilpa K; Kingwatanakul P; Deekajorndej T; Rianthavorn P; Susantitaphong P; Katavetin P; Tiranathanakul K; Srisawat N; Tungsanga K; Eiam-Ong S; Townamchai N
Nephrol Dial Transplant; 2017 Jan; 32(1):132-136. PubMed ID: 26932687
[TBL] [Abstract][Full Text] [Related]
17. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.
Hernández-Ávila M; Torres-Ibarra L; Stanley M; Salmerón J; Cruz-Valdez A; Muñoz N; Herrero R; Villaseñor-Ruíz IF; Lazcano-Ponce E
Hum Vaccin Immunother; 2016; 12(1):30-8. PubMed ID: 26211489
[TBL] [Abstract][Full Text] [Related]
19. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of HPV vaccine types 6, 11, 16 and 18 in HIV-infected and uninfected women from Brazil.
Nicol AF; Grinsztejn B; Friedman RK; Veloso VG; Cunha CB; Georg I; Pilotto JH; Moreira RI; Castro CA; Silver B; Viscidi RP
J Clin Virol; 2013 Jun; 57(2):147-51. PubMed ID: 23490398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]